or a pharmaceutically acceptable salt, or a solvate, or a solvate of the salt thereof, wherein:

X is as herein defined;

m is 1;

n is 0;

R^1 is H or C_{1-6}alkyl;

R^2 is a thiophene, furan, pyrazine, pyridine, isoxazole, benzoxazole, imidazothiazole or phenyl;

each of which may independently be optionally substituted by one or more groups independently selected from C_{1-6}alkyl, halogen, haloC_{1-6}alkyl, —CN;

R^3 is H, 4 or 5 membered cycloalkyl, imidazole, or oxetane; each of which may independently be optionally substituted by one or more groups independently selected from —C_{1-6}alkyl, —OC_{1-6}alkyl, halogen and —CN;

the moiety



is phenyl, pyridine, benzothiazole, benzofuran, each of which may independently be optionally substituted by one or more groups independently selected from —C_{1-6}alkyl, halogen, —CN, —C_{2-6}alkynyl, —C_{2-6}alkynyl-aryl, —C_{2-6}alkynyl-C_{1-6}alkyl-aryl, —C_{2-6}alkynyl-C_{1-6}alkyl-$NR^{11}R^{12}$; or a 5-6 membered heteroaryl, which may be optionally substituted by one or more groups independently selected from —$C(=O)OC_{1-6}$alkyl, thiophene, phenyl and —C_{1-6}alkyl-OH; and

R^{11} and R^{12}, which may be the same or different, are each selected from H and C_{1-6}alkyl.

80. The compound according to claim **55** comprising compounds of formula I:



I

or a pharmaceutically acceptable salt, or a solvate, or a solvate of the salt thereof, wherein:

X is as herein defined;

m is 1;

n is 0 or 2;

R^1 is H or C_{1-6}alkyl;

R^2 is a 5 or 6 membered heteroaryl, a fused 9 or 10 membered bicyclic heteroaryl, a 6 membered aryl or a 5 or 6 membered monocyclic heterocycloalkyl or a fused 8-10 membered partially unsaturated bicyclic heterocyclyl; each of which may independently be optionally substituted by one or more groups independently selected from C_{1-6}alkyl, halogen, —OC_{1-6}alkyl, —CN, —$C(=O)C_{1-6}$alkyl —$C(=O)OC_{1-6}$alkyl, —SO_2—C_{1-6}alkyl, —$C(=O)NH_2$, haloC_{1-6}alkyloxy and phenyl;

R^3 is H or C_{1-6}alkyl; or a 3-6 membered cycloalkyl, a 6 membered aryl, a 5-6 membered heteroaryl, a fused 9-10 membered bicyclic heteroaryl, a 4-6 membered monocyclic heterocycloalkyl or a 5-11 membered spiroheteroalkyl a 5-11 membered spiroheteroalkyl; each of which may independently be optionally substituted by one or more —C_{1-6}alkyl;

the moiety



is phenyl, benzodioxole, indane, pyridine, thiophene or thiazole, each of which may independently be optionally substituted by one or more groups independently selected from —C_{1-6}alkyl, halogen, haloC_{1-6}alkyl, —CN, —OC_{1-6}alkyl, —C_{1-6}alkyl-CN, —C_{2-6}alkynyl-C_{1-6}alkyl-OR^{13}, —$C(=O)C_{1-6}$alkyl, —$C(=O)NH_2$, —$C(=O)OC_{1-6}$alkyl and oxopyrrolidine a 5 or 6 membered cycloalkyl, a 4-6 membered monocyclic heterocycloalkyl, a 6 membered aryl, a 5 or 6 membered heteroaryl, a 5 or 6 membered heteroC_{3-6}cycloalkyl, each of which may independently be optionally substituted by one or more groups independently selected from —C_{1-6}alkyl, —$C(=O)OC_{1-6}$alkyl; and

R^{13} is each selected from H and C_{1-6}alkyl.

81. The compound according to claim **55** comprising compounds of formula I:



I

or a pharmaceutically acceptable salt, or a solvate, or a solvate of the salt thereof, wherein:

X and n are each as herein defined;

m is 1;

R^1 is H or C_{1-6}alkyl;

R^2 is a 5-6-membered heteroaryl, a fused 9-10 membered bicyclic heteroaryl, a 6 membered aryl or a 5-6 membered monocyclic heterocycloalkyl or a 5-11 membered spiroheteroalkyl; each of which may independently be optionally substituted by one or more groups independently selected from C_{1-6}alkyl, halogen, —CN;

R^3 is H or a 5 or 6 membered cycloalkyl, a 5 membered heteroaryl, a 6 membered monocyclic heterocycloalkyl, a 5-11 membered spiroheteroalkyl or a —C_{1-6}alkyl-heteroaryl; each of which may independently be optionally substituted by one or more groups independently selected from —C_{1-6}alkyl, halogen and —$C(=O)OC_{1-6}$alkyl;

the moiety